Skip to main content
OpenTrials
Completed

NCT Number: NCT05973409

Evaluation of Onefit Scleral Lenses in the Mangement of Dry Eye

This study is being conducted to determine if scleral lenses treated with Hydra-PEG improve comfort and dryness.

Completed

Looking for future studies?

Notify Me

Key information

Age range

17 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

School of Optometry & Vision Sciences

Waterloo, Ontario, N2L 3G1, Canada

About this study

The objective of the study is to determine if scleral lenses with and scleral lenses without Hydra-PEG treatment provide positive improvement in ocular comfort and dryness scores.

The effect of the study lenses and the treatment, will be compared in a group of symptomatic soft lens wearers, and also in a group of symptomatic non contact lens wearers.

The primary outcome variable for this study is "overall ocular comfort" reported at the screening visit for the habitual vision correction, and at the 4-week follow-up visits for each of the two study lenses. using a 0-10 scale (0.5 steps).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are at least 17 years of age and have full legal capacity to volunteer;
  • Have read and signed an information consent letter;
  • Are willing and able to follow instructions and maintain the appointment schedule;
  • Agree to wear the study scleral lenses for at least 8 hours per day, 5 days a week;
  • Have a refraction between +20.00 and -20.00D and spectacle astigmatism of no more than -3.00DC in each eye;
  • Have best corrected visual acuity of 20/40 or better in each eye with the study lenses;
  • Demonstrate an acceptable fit with the study lenses;
  • Have no active ocular disease or inflammation;
  • Group 1: Habitual wearer of frequent replacement or daily disposable soft lenses;
  • Group 2: Have not worn contact lenses for 6 months;
  • Group 1: Contact lens wearers should score ≥12 on CLDEQ-8;
  • Group 2: Non contact lens wearers should score ≥13 on OSDI.

Exclusion criteria

  • Are participating in any concurrent clinical or research study, or have done so within the past 30 days;
  • Cannot achieve a successful lens fit or vision with the study lens;
  • Have been diagnosed with keratoconus or corneal distortion;
  • Have any known active* ocular condition, disease and/or infection;
  • Have a systemic or ocular condition that in the opinion of the investigator may affect a study outcome variable e.g. pingueculae;
  • Are using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
  • Group 2: Non-contact lens wearers who score ≥33 on OSDI and also demonstrate either corneal staining ≥3 (Oxford scale) or non-invasive tear break-up time ≤3 seconds#;
  • Have known sensitivity to the diagnostic sodium fluorescein to be used in the study;
  • Are pregnant, lactating or planning a pregnancy^ at the time of enrolment, by self report;
  • Have undergone refractive error surgery;
  • Are listed on the Delegation Log for this study.

Treatment and study plan

scleral lens

Device

scleral lens with and without hydra-peg treatment

Primary outcomes

  1. overall ocular comfort

    Time frame: 4 weeks

    reported at the screening visit for the habitual vision correction, and at the 4-week follow-up visits for each of the two study lenses. using a 0-10 scale (0.5 steps)

Sponsors and collaborators

Lead sponsor

CooperVision International Limited (CVIL)

Industry

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Aug 2, 2023
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.